Acarix AB (publ) (ACARIX) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello and welcome to the Acarix Q1 2025 earnings call. Thank you for joining. We're going to get into a lot of dialogue today surrounding what we did in Q1. But most pertinently, we'll start off with all the macro economy and all the changes that are going on regarding the geopolitical situations and rhetoric, as well as a lot of these tariffs and macro economic environment surrounding logistics and most pertinently supply chain. There's many, many things that will be continually changing and evolving with the new administration in the US, but we want to make sure that our shareholders are understanding that we are very committed to understanding exactly how things are procuring as best we possibly can because they seem to change on a day to day basis. However, we're having minimal impact in regard to how we function as an organization because Most everything we do is coming out of Sweden and Denmark, where we're seeing a decent tariff per se of 10%. So it won't have a dramatic impact, but it will have a small impact on our margin as we continually move forward. But the hope is over the course of the next few months and quarters that things kind of settle and level out to something that's amicable for all governments in all different countries. With that, I'll jump in to give a little bit of an update. as I normally do regarding our company for any new shareholders that are joining us. So we are Carex. We have a medical device that is a rule out device for coronary artery disease at point of care. We are first in class. We have FDA approval. We have CE mark. We generate a test in four to six minutes. at point of care that provides a negative predictive value of 96.2%, which is fairly consistent with more invasive tests across the board. So we have a very incredible v...